CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its recent trading, with the stock last closing at US$57.69 and posting a 0.5% ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't absorb light just yet, they rely on other sources, like fatty acids. To ...

Conservation genomics is a bold new tool for protecting life on earth, but it will take all of us to slow the extinction ...

Scientists studying axolotls, zebrafish, and mice have uncovered a shared set of genes that may one day help humans regrow ...

A research team led by Prof. Hsing I-Ming, Professor of the Department of Chemical and Biological Engineering (CBE) at The ...

Individuals that share the same deletion of a portion of chromosome 16 are at risk of developing neurodevelopmental disorders ...

By Nancy Lapid April 17 (Reuters) - Researchers have developed a modified version of the CRISPR gene-editing tool that in early laboratory experiments suggests it may have the potential to “silence” ...

End-to-end pipelines and regulatory advances aim to expand gene editing to broad patient populations Ajay Gannerkote, ...

In the modern world, many people do not sleep the recommended number of hours a day, but for 1-3% of people this is not a ...

High-content screening combines automated microscopy and quantitative image analysis to measure complex cellular phenotypes ...